Zostavax

Zostavax is a vaccine used to prevent shingles in adults 50 years of age and older. It is a live vaccine that was developed by Merck & Co. and was approved by the FDA in 2006.

Composition

Zostavax is made from the same varicella zoster virus that causes chickenpox. The vaccine contains a weakened form of the virus that stimulates the immune system to produce an immune response. This response helps to protect the body against future infections with the virus.

Usage

Zostavax is given as a single injection under the skin, usually in the upper arm. The vaccine is recommended for adults 50 years of age and older, especially those who have had chickenpox. It is not used to treat shingles or nerve pain caused by shingles.

Efficacy

Studies have shown that Zostavax can reduce the risk of developing shingles by about 50%. It can also reduce the severity and duration of the disease in people who do get shingles after being vaccinated.

Side Effects

Common side effects of Zostavax include redness, pain, itching, swelling, hard lump, warmth, or bruising where the shot was given. Other side effects may include headache, muscle pain, fever, and rash.

Availability

As of November 18, 2020, Zostavax is no longer available for use in the United States, as it was replaced by a newer vaccine, Shingrix, which is more than 90% effective at preventing shingles and postherpetic neuralgia.

See Also

• Vaccine
• Shingles
• Varicella zoster virus
• Merck & Co.
• Food and Drug Administration
• Shingrix

‎

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian